212 related articles for article (PubMed ID: 37541187)
21. CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants.
Spisák S; Lawrenson K; Fu Y; Csabai I; Cottman RT; Seo JH; Haiman C; Han Y; Lenci R; Li Q; Tisza V; Szállási Z; Herbert ZT; Chabot M; Pomerantz M; Solymosi N; ; Gayther SA; Joung JK; Freedman ML
Nat Med; 2015 Nov; 21(11):1357-63. PubMed ID: 26398868
[TBL] [Abstract][Full Text] [Related]
22. Genetic variants in the cholesterol biosynthesis pathway genes and risk of prostate cancer.
Cheng Y; Meng Y; Li S; Cao D; Ben S; Qin C; Hua L; Cheng G
Gene; 2021 Mar; 774():145432. PubMed ID: 33444688
[TBL] [Abstract][Full Text] [Related]
23. The RTK/ERK pathway is associated with prostate cancer risk on the SNP level: a pooled analysis of 41 sets of data from case-control studies.
Chen Y; Li T; Yu X; Xu J; Li J; Luo D; Mo Z; Hu Y
Gene; 2014 Jan; 534(2):286-97. PubMed ID: 24177231
[TBL] [Abstract][Full Text] [Related]
24. Genome scan study of prostate cancer in Arabs: identification of three genomic regions with multiple prostate cancer susceptibility loci in Tunisians.
Shan J; Al-Rumaihi K; Rabah D; Al-Bozom I; Kizhakayil D; Farhat K; Al-Said S; Kfoury H; Dsouza SP; Rowe J; Khalak HG; Jafri S; Aigha II; Chouchane L
J Transl Med; 2013 May; 11():121. PubMed ID: 23668334
[TBL] [Abstract][Full Text] [Related]
25. Putative Prostate Cancer Risk SNP in an Androgen Receptor-Binding Site of the Melanophilin Gene Illustrates Enrichment of Risk SNPs in Androgen Receptor Target Sites.
Bu H; Narisu N; Schlick B; Rainer J; Manke T; Schäfer G; Pasqualini L; Chines P; Schweiger MR; Fuchsberger C; Klocker H
Hum Mutat; 2016 Jan; 37(1):52-64. PubMed ID: 26411452
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive functional annotation of 77 prostate cancer risk loci.
Hazelett DJ; Rhie SK; Gaddis M; Yan C; Lakeland DL; Coetzee SG; ; ; Henderson BE; Noushmehr H; Cozen W; Kote-Jarai Z; Eeles RA; Easton DF; Haiman CA; Lu W; Farnham PJ; Coetzee GA
PLoS Genet; 2014 Jan; 10(1):e1004102. PubMed ID: 24497837
[TBL] [Abstract][Full Text] [Related]
27. Functional genomic analysis delineates regulatory mechanisms of GWAS-identified bipolar disorder risk variants.
Chen R; Yang Z; Liu J; Cai X; Huo Y; Zhang Z; Li M; Chang H; Luo XJ
Genome Med; 2022 May; 14(1):53. PubMed ID: 35590387
[TBL] [Abstract][Full Text] [Related]
28. Novel role of prostate cancer risk variant rs7247241 on PPP1R14A isoform transition through allelic TF binding and CpG methylation.
Tian Y; Soupir A; Liu Q; Wu L; Huang CC; Park JY; Wang L
Hum Mol Genet; 2022 May; 31(10):1610-1621. PubMed ID: 34849858
[TBL] [Abstract][Full Text] [Related]
29. Pooled sample-based GWAS: a cost-effective alternative for identifying colorectal and prostate cancer risk variants in the Polish population.
Gaj P; Maryan N; Hennig EE; Ledwon JK; Paziewska A; Majewska A; Karczmarski J; Nesteruk M; Wolski J; Antoniewicz AA; Przytulski K; Rutkowski A; Teumer A; Homuth G; Starzyńska T; Regula J; Ostrowski J
PLoS One; 2012; 7(4):e35307. PubMed ID: 22532847
[TBL] [Abstract][Full Text] [Related]
30. CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity.
Assimon VA; Tang Y; Vargas JD; Lee GJ; Wu ZY; Lou K; Yao B; Menon MK; Pios A; Perez KC; Madriaga A; Buchowiecki PK; Rolfe M; Shawver L; Jiao X; Le Moigne R; Zhou HJ; Anderson DJ
ACS Chem Biol; 2019 Feb; 14(2):236-244. PubMed ID: 30640450
[TBL] [Abstract][Full Text] [Related]
31. Variants at IRX4 as prostate cancer expression quantitative trait loci.
Xu X; Hussain WM; Vijai J; Offit K; Rubin MA; Demichelis F; Klein RJ
Eur J Hum Genet; 2014 Apr; 22(4):558-63. PubMed ID: 24022300
[TBL] [Abstract][Full Text] [Related]
32. IRX2 regulates endometrial carcinoma oncogenesis by transcriptional repressing RUVBL1.
Xu Q; Zhou W; Zhou Y; Zhang X; Jiang R; Ai Z; Chen J; Ma L
Exp Cell Res; 2024 Jan; 434(1):113866. PubMed ID: 38042247
[TBL] [Abstract][Full Text] [Related]
33. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
[TBL] [Abstract][Full Text] [Related]
34. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk.
Jin G; Sun J; Isaacs SD; Wiley KE; Kim ST; Chu LW; Zhang Z; Zhao H; Zheng SL; Isaacs WB; Xu J
Carcinogenesis; 2011 Nov; 32(11):1655-9. PubMed ID: 21856995
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.
Hoffmann TJ; Passarelli MN; Graff RE; Emami NC; Sakoda LC; Jorgenson E; Habel LA; Shan J; Ranatunga DK; Quesenberry CP; Chao CR; Ghai NR; Aaronson D; Presti J; Nordström T; Wang Z; Berndt SI; Chanock SJ; Mosley JD; Klein RJ; Middha M; Lilja H; Melander O; Kvale MN; Kwok PY; Schaefer C; Risch N; Van Den Eeden SK; Witte JS
Nat Commun; 2017 Jan; 8():14248. PubMed ID: 28139693
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide two-locus epistasis scans in prostate cancer using two European populations.
Tao S; Feng J; Webster T; Jin G; Hsu FC; Chen SH; Kim ST; Wang Z; Zhang Z; Zheng SL; Isaacs WB; Xu J; Sun J
Hum Genet; 2012 Jul; 131(7):1225-34. PubMed ID: 22367438
[TBL] [Abstract][Full Text] [Related]
37. RUVBL1/2 Complex Regulates Pro-Inflammatory Responses in Macrophages
Zhang R; Cheung CY; Seo SU; Liu H; Pardeshi L; Wong KH; Chow LMC; Chau MP; Wang Y; Lee AR; Kwon WY; Chen S; Chan BK; Wong K; Choy RKW; Ko BCB
Front Immunol; 2021; 12():679184. PubMed ID: 34276666
[TBL] [Abstract][Full Text] [Related]
38. A genome-wide survey over the ChIP-on-chip identified androgen receptor-binding genomic regions identifies a novel prostate cancer susceptibility locus at 12q13.13.
Feng J; Sun J; Kim ST; Lu Y; Wang Z; Zhang Z; Gronberg H; Isaacs WB; Zheng SL; Xu J
Cancer Epidemiol Biomarkers Prev; 2011 Nov; 20(11):2396-403. PubMed ID: 21960693
[TBL] [Abstract][Full Text] [Related]
39. A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
Wang V; Geybels MS; Jordahl KM; Gerke T; Hamid A; Penney KL; Markt SC; Freedman M; Pomerantz M; Lee GM; Rana H; Börnigen D; Rebbeck TR; Huttenhower C; Eeles RA; Stanford JL; Consortium P; Berndt SI; Claessens F; Sørensen KD; Park JY; Vega A; Usmani N; Mucci L; Sweeney CJ
Prostate; 2021 Jul; 81(10):683-693. PubMed ID: 33956343
[TBL] [Abstract][Full Text] [Related]
40. H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility.
Giambartolomei C; Seo JH; Schwarz T; Freund MK; Johnson RD; Spisak S; Baca SC; Gusev A; Mancuso N; Pasaniuc B; Freedman ML
Am J Hum Genet; 2021 Dec; 108(12):2284-2300. PubMed ID: 34822763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
